drugset
Drugs / ZG006
last change 3 days ago re-read 2 minutes ago

ZG006

Developed for
small cell lung carcinoma · neuroendocrine carcinoma · cancer · prostate neuroendocrine neoplasm
Investigated by
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Trials 10 · a red edge is where a trial was stopped

today NCT07595913 · Ph 3 NCT07231445 · Ph 1 NCT07258121 · Ph 1/2 NCT07189455 · Ph 3 NCT07038096 · Ph 1/2 NCT07024277 · Ph 2 NCT06592638 · Ph 1 NCT06283719 · Ph 1/2 NCT06440057 · Ph 1/2 NCT05978284 · Ph 1/2
202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT07231445 Apr 2026 → Dec 2028 expected small cell lung carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase 1 NCT06592638 Mar 2025 → Dec 2026 expected small cell lung carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase 1/25 trials
Phase 1/2 NCT07258121 Dec 2025 → Dec 2028 expected cancer Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase 1/2 NCT07038096 Sep 2025 → Sep 2027 expected small cell lung carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase 1/2 NCT06283719 Sep 2024 → Apr 2026 overdue small cell lung carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase 1/2 NCT06440057 Aug 2024 → May 2026 overdue neuroendocrine carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase 1/2 NCT05978284 Oct 2023 → Sep 2026 expected small cell lung carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT07024277 Aug 2025 → Dec 2027 expected prostate neuroendocrine neoplasm Suzhou Zelgen Biopharmaceuticals Co.,Ltd Not yet recruiting No outcome recorded
Phase 32 trials
Phase 3 NCT07595913 Jul 2026 → Jun 2028 expected neuroendocrine carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd Not yet recruiting No outcome recorded
Phase 3 NCT07189455 Dec 2025 → Oct 2028 expected small cell lung carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as ZG006 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05978284 ↗
9

NCT06592638 ↗

NCT07231445 ↗

NCT06283719 ↗

NCT06440057 ↗

NCT07024277 ↗

NCT07038096 ↗

NCT07595913 ↗

NCT07258121 ↗

NCT07189455 ↗
Route Intravenous “ZG006 will be administered as an intravenous (IV) infusion.” NCT05978284 ↗